These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 35987309)

  • 1. Glycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed‑loop system: A randomized controlled trial.
    Elbarbary NS; Ismail EAR
    Diabetes Res Clin Pract; 2022 Sep; 191():110045. PubMed ID: 35987309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Glycemic Outcomes During the MiniMed
    Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
    Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
    [No Abstract]   [Full Text] [Related]  

  • 3. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
    Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
    Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
    Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
    Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
    Benhalima K; Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C
    Lancet Diabetes Endocrinol; 2024 Jun; 12(6):390-403. PubMed ID: 38697182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitigating iftar-related glycemic excursions in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed loop system: a randomized clinical trial for adjunctive oral vildagliptin therapy during Ramadan fasting.
    Elbarbary NS; Ismail EAR
    Diabetol Metab Syndr; 2023 Dec; 15(1):257. PubMed ID: 38057844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring.
    Gros Herguido N; Amuedo S; Bellido V; López Gallardo G; Losada F; Pérez Morales A; Ruiz Trillo CA; Soto Moreno A
    Diabetes Technol Ther; 2023 Feb; 25(2):151-156. PubMed ID: 36108305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 12-Month Real-Life Efficacy of the MiniMed 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.
    Lablanche S; Delagenière J; Jalbert M; Sonnet E; Benichou M; Arnold N; Spiteri A; Le Berre JP; Renard E; Chevalier N; Borot S; Bonnemaison E; Coffin C; Teissier MP; Benhamou PY; Borel JC; Penfornis A; Joubert M; Kessler L
    Diabetes Technol Ther; 2024 Jun; 26(6):426-432. PubMed ID: 38236643
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Outcomes with MiniMed
    Abraham MB; Smith GJ; Dart J; Davis EA; Jones TW
    Diabetes Technol Ther; 2024 May; 26(5):341-345. PubMed ID: 38215208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
    Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
    Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
    Castañeda J; Mathieu C; Aanstoot HJ; Arrieta A; Da Silva J; Shin J; Cohen O
    Diabetes Obes Metab; 2022 Nov; 24(11):2212-2221. PubMed ID: 35791621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes.
    Piccini B; Pessina B; Casalini E; Lenzi L; Toni S
    Pediatr Diabetes; 2022 Dec; 23(8):1647-1655. PubMed ID: 36317539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.
    Matejko B; Juza A; Kieć-Wilk B; Cyranka K; Krzyżowska S; Chen X; Cohen O; Da Silva J; Malecki MT; Klupa T
    Diabetes Care; 2022 Nov; 45(11):2628-2635. PubMed ID: 35972259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of provision of optimum diabetes care on the safety of fasting in Ramadan in adult and adolescent patients with type 1 diabetes mellitus.
    Alawadi F; Alsaeed M; Bachet F; Bashier A; Abdulla K; Abuelkheir S; Rashid F; Abdulaziz Bin Hussain A; Abdelgadir E; Alsayyah F; Elsayed M; Hassanein M
    Diabetes Res Clin Pract; 2020 Nov; 169():108466. PubMed ID: 32971155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring.
    van den Heuvel T; Kolassa R; Keuthage W; Kroeger J; Ré R; de Portu S; Vorrink L; Shin J; Castañeda J; Vigersky R; Cohen O
    J Diabetes Sci Technol; 2024 Sep; 18(5):1132-1138. PubMed ID: 36949671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-Month Effectiveness of Advanced
    Tornese G; Buzzurro F; Carletti C; Faleschini E; Barbi E
    Front Endocrinol (Lausanne); 2021; 12():766314. PubMed ID: 34858339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
    Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
    Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of advanced hybrid closed loop systems in children with type 1 diabetes younger than 6 years.
    Rapini N; Martino M; Arnaldi C; Deodati A; Anagnostopoulou L; Amodeo ME; Ciampalini P; Pampanini V; Lorubbio A; Tosini D; Cianfarani S; Schiaffini R
    Front Endocrinol (Lausanne); 2024; 15():1382920. PubMed ID: 38836230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes.
    Bassi M; Teliti M; Lezzi M; Iosca A; Strati MF; Carmisciano L; d'Annunzio G; Minuto N; Maggi D
    Front Endocrinol (Lausanne); 2021; 12():802419. PubMed ID: 35116007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.